Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Other Financing Activities
Financing cash flows not reported separately.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns positive
Q1 FY2026 other financing activities was $0, compared with -$487K a year earlier. Trailing-twelve-month other financing activities was -$74K. Over 3 fiscal years it compounded at -46.5% a year.
Context
- Other financing activities amounted to 1.8% of revenue in FY2025, down 93.6 pp from a year earlier.
- Other financing activities grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$18.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (74K) USD
- Year-over-year change
- +95.9%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74K) | +95.9% |
| FY2024 | 2024-12-31 | (1.8M) | -320.4% |
| FY2023 | 2023-12-31 | (427K) | +11.6% |
| FY2022 | 2022-12-31 | (483K) | -122.5% |
| FY2021 | 2021-12-31 | 2.15M | — |
Other Financing Activities vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 other financing activities of $74K is the 7th largest of the 10 companies compared; the peer median is $63K.
- Its year-over-year change of -99.0% is the 4th highest of 9, against a peer median of -100.1%.
- Other financing activities amounts to 3.8% of revenue for IMDX, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.42M | -42.0% | +149.9% | 4.1% | |
| LTM Mar 2026 | $709K | -106.8% | — | 2.5% | |
| LTM Mar 2026 | $599.2K | +649.0% | — | 33.6% | |
| LTM Mar 2026 | $328K | -40.9% | -9.5% | 0.9% | |
| LTM Mar 2026 | $220K | -460.7% | — | 0.4% | |
| LTM Mar 2026 | $95K | -100.3% | -54.9% | 3.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $74K | -99.0% | -46.5% | 3.8% |
| LTM Mar 2026 | $63K | -146.7% | — | 0.4% | |
| LTM Mar 2026 | $7K | — | — | — | |
| LTM Mar 2026 | $3K | -100.0% | — | 0.0% | |
| Peer median (excluding IMDX) | $63K | -100.1% | -9.5% | 1.7% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.